PA
ELVN icon

Parallel Advisors’s Enliven Therapeutics ELVN Stock Holding History

Parallel Advisors’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$863 Buy
+17
New +$722 ﹤0.01% 3713
2025
Q4 		– Sell
-491
Closed -$10.1K – 3657
2025
Q3 		$10.1K Buy
491
+463
+1,654% +$9.33K ﹤0.01% 2528
2025
Q2 		$562 Buy
28
+18
+180% +$341 ﹤0.01% 3294
2025
Q1 		$197 Buy
10
+6
+150% +$129 ﹤0.01% 3382
2024
Q4 		$90 Buy
+4
New +$104 ﹤0.01% 3445

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Parallel Advisors's ELVN Position: Q2 2026 in Review

Parallel Advisors opened a new position in Enliven Therapeutics (ELVN) in Q2 2026: 17 shares worth $863. The stake represents ﹤0.01% of the portfolio and ranks #3713 among its holdings. This is a return to the name: Parallel Advisors previously reported a position in ELVN as recently as Q3 2025.

Parallel Advisors first reported a position in ELVN in Q4 2024 and has held it in 5 quarters since. The position peaked at $10.1K in Q3 2025. 212 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Parallel Advisors held 17 shares of Enliven Therapeutics worth $863 as of Q2 2026.
  • Enliven Therapeutics was a new Parallel Advisors position in Q2 2026.
  • Enliven Therapeutics made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #3713 holding.
  • Parallel Advisors first reported a position in Enliven Therapeutics in Q4 2024 and has held it in 5 quarters since.
  • Parallel Advisors's Enliven Therapeutics position peaked at $10.1K in Q3 2025.
  • 212 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.